Enterprise Value

1.17B

Cash

532.8M

Avg Qtr Burn

-24.43M

Short % of Float

12.47%

Insider Ownership

0.47%

Institutional Own.

-

Qtr Updated

03/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
EDG-5506 Details
Becker Muscular Dystrophy

Phase 2

Data readout

EDG-5506 Details
Rare diseases, Duchenne muscular dystrophy

Phase 2

Data readout

EDG-5506 Details
Becker Muscular Dystrophy

Phase 2

Data readout

EDG-5506 Details
Rare diseases, McArdle disease, Limb-Girdle Muscular Dystrophy

Phase 2

Data readout

EDG-5506 Details
Duchenne muscular dystrophy, Rare diseases

Phase 2

Update

Sevasemten (EDG-5506) Details
Becker Muscular Dystrophy

Phase 1b

Update

EDG-7500 Details
Heart disease, Hypertrophic cardiomyopathies

Phase 1

Data readout